Company Monitoring Page for Argenx

latest headlines for company on cafepharma

Seeking sibling for Vyvgart, argenx files for FDA approval of subcutaneous efgartigimod
Fierce Pharma
Tue, 09/27/22 - 10:16 am
Tags:
Argenx, Vyvgart, myasthenia gravis, efgartigimod, FDA
As Vyvgart launch gains steam, Argenx CEO says his company can achieve 'standalone' success
Fierce Pharma
Wed, 09/14/22 - 09:41 am
Tags:
Argenx, Vyvgart, innovation, myasthenia gravis
Argenx takes a step towards convenience
EP Vantage
Wed, 03/23/22 - 10:27 am
Tags:
Argenx, efgartigimod, Vyvgart, myasthenia gravis
Argenx's Vygart launch finds quick neurologist support over AstraZeneca's well-entrenched Soliris for myasthenia gravis
Fierce Pharma
Thu, 02/17/22 - 11:13 pm
Tags:
Argenx, Vygart, myasthenia gravis, neurologists
Go or no go? Argenx's December showdown
EP Vantage
Wed, 12/1/21 - 10:10 am
Tags:
FDA, Argenx, efgartigimod, myasthenia gravis, Calliditas, Nefcon, Merck, Keytruda
From Pfizer to Argenx: A look at potential blockbusters awaiting FDA decisions this year
Fierce Pharma
Mon, 09/13/21 - 11:38 pm
Tags:
FDA, Pfizer, Argenx, UCB Pharma, Roche, efgartigimod, bimekizumab, faricimab, abrocitinib
The big approvals still on the cards for 2021
EP Vantage
Thu, 06/17/21 - 11:00 am
Tags:
FDA, drug approvals, Argenx, Novartis, AstraZeneca, Astellas, UCB Pharma, Ascendis Pharma, ChemoCentryx, Axsome Therapeutics
Johnson & Johnson culls $1.6B argenx blood cancer drug collab
Fierce Biotech
Mon, 06/7/21 - 11:02 am
Tags:
JNJ, biobucks, Belgium, Argenx, cusatuzumab
AgomAb raises $74M to develop regenerative pathway modulators
Fierce Biotech
Wed, 03/10/21 - 10:34 am
Tags:
AgomAb, regenerative pathway modulators, Argenx
Aducanumab tops 2021’s biggest potential launches
EP Vantage
Mon, 01/18/21 - 01:04 pm
Tags:
drug launches, Biogen, Eisai, aducanumab, efgartigimod, Argenx, Evrenzo, FibroGen, Astellas, AstraZeneca, Leqvio, Novartis, UCB Pharma, bimekizumab, Ascendis Pharma, Bluebird Bio, Bristol-Myers Squibb, ide-cel, liso-cel, AXS-05, Axsome Therapeutics, voclosporin, Aurinia
Biopharma Companies Entering 2021 With New Collabs, Partnerships
BioSpace
Sat, 01/9/21 - 07:42 pm
Tags:
M&A, Argenx, Zai Lab, Dewpoint Therapeutics, Pfizer, CureVac, Bayer, Sanofi, Nurix Therapeutics
3 Biotech Stocks That Could Explode Higher in 2021
Motley Fool
Mon, 12/21/20 - 10:58 am
Tags:
biotech, biotech stocks, clinical trials, FDA, Argenx, Axsome Therapeutics, CRISPR Therapeutics
Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M
Fierce Biotech
Mon, 11/23/20 - 10:16 am
Tags:
Argenx, Bayer, FDA, priority reviews, efgartigimod, ITP
10 most valuable R&D projects in the pharmaceutical industry pipeline
Beckers Hospital Review
Mon, 07/20/20 - 11:49 pm
Tags:
R&D, drug development, Eli Lilly, Novartis, Argenx, Bristol-Myers Squibb, Vir Biotechnolgy, Biogen, GSK, Iovance, Roche
Biotech Argenx's autoimmune phase 3 hits goals, teeing up FDA filing
Fierce Biotech
Tue, 05/26/20 - 11:07 am
Tags:
Argenx, efgartigimod, myasthenia gravis
Upcoming events – Wave takes on Huntington's and Argenx goes subcutaneous
EP Vantage
Fri, 11/15/19 - 11:14 am
Tags:
Wave Life Sciences, WVE-120101, Huntington's disease, Argenx, efgartigimod, autoimmune disease
Argenx and Halozyme Ink Multiple Target Deal That Could Hit $540 Million
BioSpace
Mon, 02/4/19 - 11:33 am
Tags:
Argenx, Halozyme Therapeutics, drug delivery, drug development
Should You Be Worried About the Return of Big Pharma Deals?
Motley Fool
Tue, 12/4/18 - 11:27 am
Tags:
GSK, Tesaro, M&A, Big Pharma, JNJ, Argenx
ASH18: Argenx pens $1.6B biobucks Janssen pact for blood cancer hopeful cusatuzumab
Fierce Biotech
Mon, 12/3/18 - 09:55 am
Tags:
Argenx, Cilag, Janssen, cusatuzumab, ASH2018, blood cancers
Argenx To Raise $300 million in U.S. public offering
CP Wire
Wed, 09/19/18 - 11:44 am
Tags:
Argenx

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.